%0 Journal Article
%A Adolph, Jonas E
%A Fleischhack, Gudrun
%A Gaab, Christine
%A Mikasch, Ruth
%A Mynarek, Martin
%A Rutkowski, Stefan
%A Schüller, Ulrich
%A Pfister, Stefan M
%A Pajtler, Kristian
%A Milde, Till
%A Witt, Olaf
%A Bison, Brigitte
%A Warmuth-Metz, Monika
%A Kortmann, Rolf-Dieter
%A Dietzsch, Stefan
%A Pietsch, Torsten
%A Timmermann, Beate
%A Tippelt, Stephan
%T Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies.
%J Journal of neuro-oncology
%V 155
%N 2
%@ 1573-7373
%C Dordrecht [u.a.]
%I Springer Science + Business Media B.V
%M DKFZ-2021-02286
%P 193-202
%D 2021
%Z 2021 Nov;155(2):193-202
%X Survival in recurrent ependymoma (EPN) depends mainly on the extent of resection achieved. When complete resection is not feasible, chemotherapy is often used to extend progression-free and overall survival. However, no consistent effect of chemotherapy on survival has been found in patients with recurrent EPN.Systemic chemotherapeutic treatment of 138 patients enrolled in the German HIT-REZ-studies was analyzed. Survival depending on the use of chemotherapy, disease-stabilization rates (RR), duration of response (DOR) and time to progression (TTP) were estimated.Median age at first recurrence was 7.6 years (IQR: 4.0-13.6). At first recurrence, median PFS and OS were 15.3 (CI 13.3-20.0) and 36.9 months (CI 29.7-53.4), respectively. The Hazard Ratio for the use of chemotherapy in local recurrences in a time-dependent Cox-regression analysis was 0.99 (CI 0.74-1.33). Evaluable responses for 140 applied chemotherapies were analyzed, of which sirolimus showed the best RR (50
%K Chemotherapy (Other)
%K Children (Other)
%K Ependymoma (Other)
%K Recurrence (Other)
%K Sirolimus (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:34657224
%R 10.1007/s11060-021-03867-8
%U https://inrepo02.dkfz.de/record/177080